The stock of Artiva Biotherapeutics Inc (NASDAQ: ARTV) has decreased by -12.04 when compared to last closing price of 14.29.Despite this, the company has seen a loss of -15.41% in its stock price over the last five trading days. globenewswire.com reported 2024-09-10 that SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m.
Is It Worth Investing in Artiva Biotherapeutics Inc (NASDAQ: ARTV) Right Now?
Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARTV is 12.32M, and currently, short sellers hold a 6.83% ratio of that floaft. The average trading volume of ARTV on October 16, 2024 was 172.90K shares.
ARTV’s Market Performance
The volatility ratio for the week is 12.45%, and the volatility levels for the last 30 days are 10.86% for Artiva Biotherapeutics Inc (ARTV). The simple moving average for the past 20 days is -10.86% for ARTV’s stock, with a 3.40% simple moving average for the past 200 days.
Analysts’ Opinion of ARTV
Many brokerage firms have already submitted their reports for ARTV stocks, with Wedbush repeating the rating for ARTV by listing it as a “Outperform.” The predicted price for ARTV in the upcoming period, according to Wedbush is $18 based on the research report published on August 13, 2024 of the current year 2024.
Needham gave a rating of “Buy” to ARTV, setting the target price at $23 in the report published on August 13th of the current year.
ARTV Trading at 2.62% from the 50-Day Moving Average
After a stumble in the market that brought ARTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.38% of loss for the given period.
Volatility was left at 10.86%, however, over the last 30 days, the volatility rate increased by 12.45%, as shares surge +14.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.24% upper at present.
During the last 5 trading sessions, ARTV fell by -15.41%, in comparison to the 20-day moving average, which settled at $14.10. In addition, Artiva Biotherapeutics Inc saw 4.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARTV starting from RA CAPITAL MANAGEMENT, L.P., who purchase 8,333,333 shares at the price of $12.00 back on Jul 22 ’24. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 8,693,579 shares of Artiva Biotherapeutics Inc, valued at $99,999,996 using the latest closing price.
5AM Partners VI, LLC, the 10% Owner of Artiva Biotherapeutics Inc, purchase 833,333 shares at $12.00 during a trade that took place back on Jul 22 ’24, which means that 5AM Partners VI, LLC is holding 1,182,054 shares at $9,999,996 based on the most recent closing price.
Stock Fundamentals for ARTV
Current profitability levels for the company are sitting at:
- -122.24 for the present operating margin
- 1.0 for the gross margin
The net margin for Artiva Biotherapeutics Inc stands at -123.36. The total capital return value is set at -0.47.
Based on Artiva Biotherapeutics Inc (ARTV), the company’s capital structure generated -0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -1.82.
Currently, EBITDA for the company is -29.11 million with net debt to EBITDA at 0.59. When we switch over and look at the enterprise to sales, we see a ratio of 1217.92. The receivables turnover for the company is 0.17for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
In a nutshell, Artiva Biotherapeutics Inc (ARTV) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
